Literature DB >> 27758931

Impact of Substrate-Dependent Inhibition on Renal Organic Cation Transporters hOCT2 and hMATE1/2-K-Mediated Drug Transport and Intracellular Accumulation.

Jia Yin1, Haichuan Duan1, Joanne Wang2.   

Abstract

Renal transporter-mediated drug-drug interactions (DDIs) are of significant clinical concern, as they can adversely impact drug disposition, efficacy, and toxicity. Emerging evidence suggests that human renal organic cation transporter 2 (hOCT2) and multidrug and toxin extrusion proteins 1 and 2-K (hMATE1/2-K) exhibit substrate-dependent inhibition, but their impact on renal drug secretion and intracellular accumulation is unknown. Using metformin and atenolol as the probe substrates, we found that the classic inhibitors (e.g., cimetidine) of renal organic cation secretion were approximately 10-fold more potent for hOCT2 when atenolol was used, suggesting that atenolol is a more sensitive in vitro substrate for hOCT2 than metformin. In contrast, inhibition of hMATE1/2-K was influenced much less by the choice of substrate. Cimetidine is a much more potent inhibitor for hMATE1/2-K when metformin is the substrate but acts as an equally potent inhibitor of hOCT2 and hMATE1/2-K when atenolol is the substrate. Using hOCT2/hMATE1 double-transfected Madin-Darby canine kidney cells, we evaluated the impact of substrate-dependent inhibition on hOCT2/hMATE1-mediated transepithelial flux and intracellular drug accumulation. At clinically relevant concentrations, cimetidine dose dependently inhibited basal-to-apical flux of atenolol and metformin but impacted their intracellular accumulation differently, indicating that substrate-dependent inhibition may shift the major substrate-inhibitor interaction site between apical and basolateral transporters. Cimetidine is effective only when applied to the basal compartment. Our findings revealed the complex and dynamic nature of substrate-dependent inhibition of renal organic cation drug transporters and highlighted the importance of considering substrate-dependent inhibition in predicting transporter-mediated renal drug interaction, accumulation, and toxicity.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27758931      PMCID: PMC5118648          DOI: 10.1124/jpet.116.236158

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  38 in total

Review 1.  Mechanisms and clinical implications of renal drug excretion.

Authors:  R Masereeuw; F G Russel
Journal:  Drug Metab Rev       Date:  2001 Aug-Nov       Impact factor: 4.518

2.  A human transporter protein that mediates the final excretion step for toxic organic cations.

Authors:  Masato Otsuka; Takuya Matsumoto; Riyo Morimoto; Shigeo Arioka; Hiroshi Omote; Yoshinori Moriyama
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-05       Impact factor: 11.205

Review 3.  Membrane transporters in drug development.

Authors:  Kathleen M Giacomini; Shiew-Mei Huang; Donald J Tweedie; Leslie Z Benet; Kim L R Brouwer; Xiaoyan Chu; Amber Dahlin; Raymond Evers; Volker Fischer; Kathleen M Hillgren; Keith A Hoffmaster; Toshihisa Ishikawa; Dietrich Keppler; Richard B Kim; Caroline A Lee; Mikko Niemi; Joseph W Polli; Yuichi Sugiyama; Peter W Swaan; Joseph A Ware; Stephen H Wright; Sook Wah Yee; Maciej J Zamek-Gliszczynski; Lei Zhang
Journal:  Nat Rev Drug Discov       Date:  2010-03       Impact factor: 84.694

Review 4.  Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney.

Authors:  Hideyuki Motohashi; Ken-ichi Inui
Journal:  AAPS J       Date:  2013-02-22       Impact factor: 4.009

Review 5.  In vitro methods to support transporter evaluation in drug discovery and development.

Authors:  K L R Brouwer; D Keppler; K A Hoffmaster; D A J Bow; Y Cheng; Y Lai; J E Palm; B Stieger; R Evers
Journal:  Clin Pharmacol Ther       Date:  2013-04-10       Impact factor: 6.875

6.  Functional characteristics and steroid hormone-mediated regulation of an organic cation transporter in Madin-Darby canine kidney cells.

Authors:  Y Shu; C L Bello; L M Mangravite; B Feng; K M Giacomini
Journal:  J Pharmacol Exp Ther       Date:  2001-10       Impact factor: 4.030

Review 7.  Emerging transporters of clinical importance: an update from the International Transporter Consortium.

Authors:  K M Hillgren; D Keppler; A A Zur; K M Giacomini; B Stieger; C E Cass; L Zhang
Journal:  Clin Pharmacol Ther       Date:  2013-04-08       Impact factor: 6.875

8.  Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.

Authors:  Matthias B Wittwer; Arik A Zur; Natalia Khuri; Yasuto Kido; Alan Kosaka; Xuexiang Zhang; Kari M Morrissey; Andrej Sali; Yong Huang; Kathleen M Giacomini
Journal:  J Med Chem       Date:  2013-01-22       Impact factor: 7.446

9.  Substrate-dependent ligand inhibition of the human organic cation transporter OCT2.

Authors:  Mathew Belzer; Mark Morales; Bhumasamudram Jagadish; Eugene A Mash; Stephen H Wright
Journal:  J Pharmacol Exp Ther       Date:  2013-05-24       Impact factor: 4.030

10.  Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters.

Authors:  Yuko Tanihara; Satohiro Masuda; Tomoko Sato; Toshiya Katsura; Osamu Ogawa; Ken-Ichi Inui
Journal:  Biochem Pharmacol       Date:  2007-04-13       Impact factor: 5.858

View more
  15 in total

1.  Assessment of Substrate-Dependent Ligand Interactions at the Organic Cation Transporter OCT2 Using Six Model Substrates.

Authors:  Philip J Sandoval; Kimberley M Zorn; Alex M Clark; Sean Ekins; Stephen H Wright
Journal:  Mol Pharmacol       Date:  2018-06-08       Impact factor: 4.436

2.  Interaction and Transport of Methamphetamine and its Primary Metabolites by Organic Cation and Multidrug and Toxin Extrusion Transporters.

Authors:  David J Wagner; Jennifer E Sager; Haichuan Duan; Nina Isoherranen; Joanne Wang
Journal:  Drug Metab Dispos       Date:  2017-04-20       Impact factor: 3.922

3.  Fampridine is a Substrate and Inhibitor of Human OCT2, but not of Human MATE1, or MATE2K.

Authors:  Guangqing Xiao; Christopher Rowbottom; Carri Boiselle; Liang-Shang Gan
Journal:  Pharm Res       Date:  2018-06-18       Impact factor: 4.200

4.  Emerging Roles of the Human Solute Carrier 22 Family.

Authors:  Sook Wah Yee; Kathleen M Giacomini
Journal:  Drug Metab Dispos       Date:  2021-12-17       Impact factor: 3.579

5.  Characterization of Meta-Iodobenzylguanidine (mIBG) Transport by Polyspecific Organic Cation Transporters: Implication for mIBG Therapy.

Authors:  Antonio J López Quiñones; David J Wagner; Joanne Wang
Journal:  Mol Pharmacol       Date:  2020-06-02       Impact factor: 4.436

6.  The Importance of Incorporating OCT2 Plasma Membrane Expression and Membrane Potential in IVIVE of Metformin Renal Secretory Clearance.

Authors:  Vineet Kumar; Jia Yin; Sarah Billington; Bhagwat Prasad; Colin D A Brown; Joanne Wang; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2018-08-09       Impact factor: 3.922

Review 7.  Molecular and cellular physiology of organic cation transporter 2.

Authors:  Stephen H Wright
Journal:  Am J Physiol Renal Physiol       Date:  2019-11-04

8.  Cationic Compounds with SARS-CoV-2 Antiviral Activity and Their Interaction with Organic Cation Transporter/Multidrug and Toxin Extruder Secretory Transporters.

Authors:  Lucy Martinez-Guerrero; Xiaohong Zhang; Kimberley M Zorn; Sean Ekins; Stephen H Wright
Journal:  J Pharmacol Exp Ther       Date:  2021-07-12       Impact factor: 4.402

9.  Kinetic basis of metformin-MPP interactions with organic cation transporter OCT2.

Authors:  Philip J Sandoval; Mark Morales; Timothy W Secomb; Stephen H Wright
Journal:  Am J Physiol Renal Physiol       Date:  2019-07-17

10.  Identification of Drug Transporter Genomic Variants and Inhibitors That Protect Against Doxorubicin-Induced Cardiotoxicity.

Authors:  Tarek Magdy; Mariam Jouni; Hui-Hsuan Kuo; Carly J Weddle; Davi Lyra-Leite; Hananeh Fonoudi; Marisol Romero-Tejeda; Mennat Gharib; Hoor Javed; Giovanni Fajardo; Colin J D Ross; Bruce C Carleton; Daniel Bernstein; Paul W Burridge
Journal:  Circulation       Date:  2021-12-07       Impact factor: 39.918

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.